Tick-borne encephalitis future or investigational new therapies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Tick-borne encephalitis}} {{CMG}} {{AE}} {{IMD}} ==Overview== An investigational new therapy, Phosphrenyl treatment, similar to interferon treatment for Hepat...") |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
An investigational new therapy, Phosphrenyl treatment, similar to [[interferon]] treatment for Hepatitis C, is the mainstay investigational treatment in treating tick-borne encephalitis. [[Antibiotic]] therapies are useful as many disease vectors responsible for transmission of tick-borne encephalitis also carry many other tick-borne diseases. An [[antibiotic]] therapy may be helpful in anticipating any potential tick-borne co-infections. | An [[Investigational New Drug|investigational new therapy]], Phosphrenyl treatment, similar to [[interferon]] treatment for [[Hepatitis C]], is the mainstay investigational treatment in treating tick-borne encephalitis. [[Antibiotic]] therapies are useful as many disease [[Vector|vectors]] responsible for [[transmission]] of tick-borne encephalitis also carry many other tick-borne diseases. An [[antibiotic]] therapy may be helpful in anticipating any potential tick-borne co-infections. | ||
==Future and Investigational New Therapies== | ==Future and Investigational New Therapies== | ||
*The mainstay investigational therapy for tick-borne encephalitis is Phosphrenyl treatment. | *The mainstay [[Investigational New Drug|investigational therapy]] for tick-borne encephalitis is Phosphrenyl treatment. | ||
*Phosphrenyl treatment including both a therapeutic and prophylactic agent for TBE | *Phosphrenyl treatment including both a [[therapeutic]] and [[prophylactic]] agent for TBE | ||
*[[Antibiotic]] treatment may be necessary for potential tick-borne co-infections | *[[Antibiotic]] treatment may be necessary for potential [[Tick-borne disease|tick-borne]], co-infections.<ref>Streptomycin--an activator of persisting tick-borne encephalitis virus.{{cite journal | author = Malenko G, Pogodina V, Karmysheva V | title = [Streptomycin--an activator of persisting tick-borne encephalitis virus] | journal = Vopr Virusol | volume = 29 | issue = 2 | pages = 217-23 | year = 1984 | month=Mar-Apr | id = PMID 6730440}}</ref><ref>Experimental phytotherapy of tick-borne encephalitis.{{cite journal | author = Fokina G, Frolova T, Roĭkhel' V, Pogodina V | title = [Experimental phytotherapy of tick-borne encephalitis] | journal = Vopr Virusol | volume = 36 | issue = 1 | pages = 18-21 | year = 1991 | month=Jan-Feb | id = PMID 1858353}}</ref><ref>Protective effect of a new antiviral preparation of phosprenyl in experimental tick-borne encephalitis.{{cite journal | author = Ozherelkov S, Timofeev A, Novikova G, Deeva A, Narovlianskiĭ A, Sanin A, Pronin A | title = [Protective effect of a new antiviral preparation of phosprenyl in experimental tick-borne encephalitis] | journal = Vopr Virusol | volume = 45 | issue = 1 | pages = 33-7 | year = 2000 | month=Jan-Feb | id = PMID 10695042}} </ref> | ||
==References== | ==References== | ||
Latest revision as of 14:41, 10 March 2016
|
Tick-borne encephalitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tick-borne encephalitis future or investigational new therapies On the Web |
|
American Roentgen Ray Society Images of Tick-borne encephalitis future or investigational new therapies |
|
FDA on Tick-borne encephalitis future or investigational new therapies |
|
CDC on Tick-borne encephalitis future or investigational new therapies |
|
Tick-borne encephalitis future or investigational new therapies in the news |
|
Blogs on Tick-borne encephalitis future or investigational new therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ilan Dock, B.S.
Overview
An investigational new therapy, Phosphrenyl treatment, similar to interferon treatment for Hepatitis C, is the mainstay investigational treatment in treating tick-borne encephalitis. Antibiotic therapies are useful as many disease vectors responsible for transmission of tick-borne encephalitis also carry many other tick-borne diseases. An antibiotic therapy may be helpful in anticipating any potential tick-borne co-infections.
Future and Investigational New Therapies
- The mainstay investigational therapy for tick-borne encephalitis is Phosphrenyl treatment.
- Phosphrenyl treatment including both a therapeutic and prophylactic agent for TBE
- Antibiotic treatment may be necessary for potential tick-borne, co-infections.[1][2][3]
References
- ↑ Streptomycin--an activator of persisting tick-borne encephalitis virus.Malenko G, Pogodina V, Karmysheva V (1984). "[Streptomycin--an activator of persisting tick-borne encephalitis virus]". Vopr Virusol. 29 (2): 217–23. PMID 6730440. Unknown parameter
|month=ignored (help) - ↑ Experimental phytotherapy of tick-borne encephalitis.Fokina G, Frolova T, Roĭkhel' V, Pogodina V (1991). "[Experimental phytotherapy of tick-borne encephalitis]". Vopr Virusol. 36 (1): 18–21. PMID 1858353. Unknown parameter
|month=ignored (help) - ↑ Protective effect of a new antiviral preparation of phosprenyl in experimental tick-borne encephalitis.Ozherelkov S, Timofeev A, Novikova G, Deeva A, Narovlianskiĭ A, Sanin A, Pronin A (2000). "[Protective effect of a new antiviral preparation of phosprenyl in experimental tick-borne encephalitis]". Vopr Virusol. 45 (1): 33–7. PMID 10695042. Unknown parameter
|month=ignored (help)